Brenus Pharma

Executive Summary

Brenus Pharma is a French biotechnology company pioneering next-generation off-the-shelf in vivo immunotherapies for solid tumors. Founded in 2020 and headquartered in Lyon, the company leverages a proprietary platform designed to mimic cancer's natural mechanisms, thereby reprogramming the immune system to stay ahead of tumor evolution. This approach aims to overcome key challenges in immuno-oncology, such as tumor heterogeneity and immune evasion, by delivering a versatile therapeutic modality that can be administered without patient-specific customization. Brenus Pharma is currently advancing its lead candidate through Phase 1/2 clinical trials, targeting multiple solid tumor indications. The platform's off-the-shelf nature offers significant scalability and cost advantages over personalized cell therapies, positioning the company as a potential leader in the rapidly evolving immuno-oncology landscape.

Upcoming Catalysts (preview)

• Q4 2026Initial Phase 1/2 safety and efficacy data readout45% success
• H2 2026Strategic partnership or licensing deal for platform technology30% success
• Q3 2026Regulatory clearance for additional clinical trial sites or indications60% success